Profil
Maria Fe Paz de Paz is the founder of Connect by Circular-Lab SL, serving as Chairwoman since 2020.
Ms. de Paz is the founder of Diaceutics Plc, holding the title of Chief Medical Officer & Director from 2009 to 2016.
Ms. de Paz is the founder of Article25.
Capital Partners, working as Partner since 2019.
Formerly, Independent Director at Aiforia Technologies Oyj from 2022 to 2025.
Chief Medical Officer at Rosetta Genomics, Inc. from 2015 to 2016.
Postes actifs de Maria Fe Paz de Paz
| Sociétés | Poste | Début |
|---|---|---|
Recovid Solutions SL
Recovid Solutions SL Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Fondateur | 01/01/2020 |
Article25 Capital Partners | Fondateur | 01/01/2019 |
Anciens postes connus de Maria Fe Paz de Paz
| Sociétés | Poste | Fin |
|---|---|---|
| AIFORIA TECHNOLOGIES OYJ | Directeur/Membre du Conseil | 04/04/2025 |
Rosetta Genomics, Inc.
Rosetta Genomics, Inc. Medical/Nursing ServicesHealth Services Operates as a molecular diagnostics company | Directeur Technique/Scientifique/R&D | 01/01/2016 |
| DIACEUTICS PLC | Fondateur | 01/01/2016 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Aiforia Technologies Oyj
Aiforia Technologies Oyj Packaged SoftwareTechnology Services Provides software solutions and versatile interfaces of digital virtual microscopy | Technology Services |
Rosetta Genomics, Inc.
Rosetta Genomics, Inc. Medical/Nursing ServicesHealth Services Operates as a molecular diagnostics company | Health Services |
Diaceutics Plc
Diaceutics Plc BiotechnologyHealth Technology Engages in research and development in medicine drug development and diagnostic tests development | Health Technology |
Recovid Solutions SL
Recovid Solutions SL Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Article25 Capital Partners |
















